Background: Dementia represents one of the greatest global health challenges. There are known risk factors that might prevent or delay nearly 50% of the different types of dementia. There are substantial differences in risk factors and progression of dementia between women and men, including engagement in regular physical activity. The study aimed to quantify the impact of increasing women's participation in physical activity with off-road cycles and its effect on dementia incidence, relative to men and the associated health and social care costs.
Methods: Our study employed a population model with secondary data analysis approach to investigate the potential economic effect of implementing off-cycle lanes in the UK. Data were drawn from published evidence on lifetime risk of dementia relative to physical activity in men and women for the UK population, levels of physical activity in the UK, evidence on the effectiveness of off-road cycle lanes in increasing the level of physical activity in men and women, lifetime costs of dementia in the UK. Two scenarios were compared, assuming an increase from the baseline levels of cycling of 40.3% and 114% for women and by 36.4% and 77% for men, respectively. Sensitivity analysis was conducted to account for variations in key variables.
Results: Current dementia related lifetime costs were estimated at £1090.1 billion, and total lifetime costs £3326.1 billion. Under Scenario 1, dementia related lifetime costs decreased by £4.7 billion, and total lifetime costs by £0.11 billion. In Scenario 2, dementia related lifetime costs decreased by £7.0 billion, and total lifetime costs by £1.9 billion.
Conclusion: Off-road cycle lanes, especially for women, this type of structural and lifestyle intervention has the potential to bring health and economic benefits. Increased physical activity not only provides numerous health benefits, but also contributes to preventing the onset and lifetime costs of dementia.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1002/gps.70067 | DOI Listing |
Value Health Reg Issues
March 2025
Division of Pulmonary Medicine, UP Manila College of Medicine and Philippine General Hospital, Ermita, Manila, Philippines.
Objectives: The Philippine National Immunization Program guidelines recommend using the 23-valent pneumococcal polysaccharide vaccine (PPV23) among senior citizens. We conducted cost-effectiveness analyses to assess the impact of replacing 2-dose PPV23 with PCV13 in all adults aged ≥60 years and expanding the recommendation to include PCV13 for adults aged 18 to 59 years at elevated risk of disease (moderate-/high-risk).
Methods: Lifetime risks and costs of invasive pneumococcal disease, nonbacteremic pneumococcal pneumonia (NBPP), and expected impact of vaccination were projected using a probabilistic cohort model.
Pharmacoeconomics
March 2025
GSK, Wavre, Belgium.
Background And Objective: Invasive meningococcal disease (IMD) is an uncommon but serious disease associated with a risk of death and severe long-term sequelae, impacting both patients and their caregivers. Productivity losses due to IMD have not previously been comprehensively evaluated in the USA. This study evaluated both market and non-market productivity losses to better estimate the economic burden of IMD in the USA.
View Article and Find Full Text PDFEur J Nucl Med Mol Imaging
March 2025
Department of Medical Imaging, Radboud University Medical Center, Radboud Institute for Health Sciences, Nijmegen, The Netherlands.
Background: Prostate-specific membrane antigen (PSMA) positron emission tomography/computed tomography (PET/CT) is currently under evaluation for detecting clinically significant prostate cancer. The PSMA-PET/CT may complement the current standard diagnostic pathway for prostate cancer, which includes prostate-specific antigen (PSA) testing and multiparametric magnetic resonance imaging (mpMRI). This study evaluated the cost-effectiveness and quality of life impact of incorporating PSMA-PET/CT into this diagnostic algorithm.
View Article and Find Full Text PDFBMC Med
March 2025
Health Economics and Policy Evaluation Research (HEPER) Group, Centre for Medicine Use and Safety, Faculty of Pharmacy and Pharmaceutical Sciences, Monash University, Melbourne, Australia.
Background: Long-term cost-effectiveness analyses of health behaviour interventions to effectively manage type 2 diabetes mellitus (T2DM) in low-income countries are crucial for minimising economic burden and optimising resource allocation. Therefore, this study aimed to estimate the long-term cost-effectiveness of implementing a health behaviour intervention to manage T2DM in Nepal.
Methods: A Markov model in combination with a decision tree was developed to compare the costs and outcomes of the health behaviour intervention against usual care among 481 (238-intervention and 243-control) participants from healthcare system and societal perspectives.
ESC Heart Fail
March 2025
Department of Pharmacy, Yantai Yuhuangding Hospital, Yantai, Shandong, China.
Aims: The study aimed to analyse the cost-utility of Chinese patent medicine Qili Qiangxin (QLQX) capsules in heart failure with a reduced ejection fraction from the healthcare payer's perspective.
Methods And Results: From the perspective of the healthcare payer, a Markov model was established to estimate the cost-utility of adding QLQX capsules to standard treatment versus standard treatment. A 19-year lifetime horizon was chosen with a 3-month cycle in the base case analysis.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!